Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
GBIO Stock Chart & Stats
$5.61
-$0.05(-4.79%)
At close: 4:00 PM EST
$5.61
-$0.05(-4.79%)
Day’s Range― - ―
52-Week Range$3.00 - $8.66
Previous CloseN/A
Volume226.22K
Average Volume (3M)52.92K
Market Cap
$37.60M
Enterprise Value$41.96M
Total Cash (Recent Filing)$89.62M
Total Debt (Recent Filing)$26.10M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 12, 2026EPS Estimate
-5.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding6,737,899
10 Day Avg. Volume46,579
30 Day Avg. Volume52,917
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)0.82
Price to Sales (P/S)3.55
P/FCF Ratio-0.78
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.75
Enterprise Value/Gross Profit3.03
Enterprise Value/Ebitda-0.72
Forecast
1Y Price Target
$5.25Price Target Upside-6.42% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deal StructureContingent value right in the acquisition deal provides potential additional payout that can help bridge the valuation gap for shareholders.
Preclinical EfficacySuccessful siRNA delivery and potent target knockdown in non-human primates demonstrate the platform's ability to achieve meaningful biological effects in relevant immune cells.
Translational SafetyAbsence of immune activation in preclinical studies reduces a key translational risk and supports potential application across multiple T-cell driven autoimmune diseases.
Bears Say
Clinical Development RiskPrograms remaining at early stages of development will require substantial work and successful clinical proof of concept before generating significant commercial value.
Offer ValuationOffer price that is below the stock's pre-deal trading level may result in a lower immediate realization than prior market expectations.
Operational RestructuringLarge planned workforce reduction combined with active evaluation of strategic alternatives increases execution risk and could push the company toward asset sales or fragmented value outcomes.
Generation Bio News
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $3.00 and its highest was $8.66 in the past 12 months.
What is Generation Bio Co.’s market cap?
Generation Bio Co.’s market cap is $37.60M.
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is Mar 12, 2026 which is in 41 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Nov 05, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$3.15 by $2.33.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Overvalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -5.5.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 6,737,899 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.82 in its last earnings report, beating expectations of -$3.15. Following the earnings report the stock price went down -3.276%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Currently, no hedge funds are holding shares in GBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Generation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.25 (-6.42% Downside)
$5.25 (-6.42% Downside)
Hedge Fund Trend
Increased
By 59.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.24%
12-Months-Change
Fundamentals
Return on Equity
-80.81%
Trailing 12-Months
Asset Growth
-32.36%
Trailing 12-Months
Company Description
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
GBIO Stock 12 Month Forecast
Average Price Target
$5.25
▼(-6.42% Downside)
Technical Analysis
Ownership Overview
Currently, No data available
---